Brief: Blinklab Receives US Ethics Approval For Main Phase Of FDA 510(K) Diagnostic Trial
30/06/2025 02:28
June 30 (Reuters) - BlinkLab Ltd BB1.AX: RECEIVES US ETHICS APPROVAL FOR MAIN PHASE OF FDA 510(K) DIAGNOSTIC TRIAL Further company coverage: BB1.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BlinkLab
See all newsAustralia's BlinkLab hits four-month high on positive ADHD study results
Brief: BlinkLab Seeks Trading Halt
Brief: BlinkLab Partners With Escuela Superior Politécnica De Chimborazo On Large-Scale Ecuador Autism Study
Australia's BlinkLab falls on discounted placement
Brief: Blinklab Secures A$17.5M To Launch Autism Diagnostic Aid